{
  "docId": "019de073-b41a-7298-b152-a88168c594ee",
  "docSlug": "fcd1785019fd61535487d85f646654d9",
  "documentTitle": "Enochian Biosciences | Investor Presentation Deck | 39 slides",
  "authorId": "enochian-biosciences",
  "authorName": "Enochian BioSciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 29,
  "pageCount": 39,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Mentions a specific cost range ($300k-$450k) as a pain point for current CAR-T therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b41a-7298-b152-a88168c594ee/29",
  "deckHref": "/decks/019de073-b41a-7298-b152-a88168c594ee",
  "deckJsonHref": "/decks/019de073-b41a-7298-b152-a88168c594ee.json",
  "deckAnchorHref": "/decks/019de073-b41a-7298-b152-a88168c594ee#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.85,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "Caring Cross, a non-profit corporation, has shown that their proprietary CAR-T cells cure HIV in a mouse model; studies in humans have begun. CAR-T is a promising therapy, but the selection of the cells is difficult, increasing cost ($300,000-$450,000 per person) and side effects. Enochian’s proprietary “special sauce” technology that could increase uptake of transplanted cells for ENOB-HV-01 could also potentially enhance the selection of CAR-T cells. Enochian has entered into a profit-sharing sub-license with Caring Cross for a key component of this technology.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59112ac1-deb9-4dda-88a2-8ea803396124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "If successful, this approach to CAR-T gene therapy could increase the selection of cells, potentially decreasing cost and side effects and expanding the number of people who could be treated. Enochian would share in profits if the product is commercialized",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08007e02-abf4-48d9-a23f-3eeb95c6cf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.09
      },
      "kind": "title",
      "text": "ENOB-HV-01: POTENTIAL TO INCREASE SELECTION OF CAR-T CELLS FOR HIV TREATMENT OR CURE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "994fec92-681e-441e-9120-551498f37fa6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a0da9913-f5d6-4706-819a-fb668d9535d7",
      "evidence": "ENOB-HV-01: POTENTIAL TO INCREASE SELECTION OF CAR-T CELLS FOR HIV TREATMENT OR CURE",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}